BMS-202

BMS-202
Clinical data
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-(2-(((2-methoxy-6-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)pyridin-3-yl)methyl)amino)ethyl)acetamide;
CAS Number	1675203-84-5 ;
PubChem CID	117951478;
IUPHAR/BPS	9607;
ChemSpider	45743495;
UNII	KDA2HUE7KP;
ChEMBL	ChEMBL4089730 ;
Chemical and physical data
Formula	C25H29N3O3
Molar mass	419.525 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC=C1C2=CC=CC=C2)COC3=NC(=C(C=C3)CNCCNC(=O)C)OC;
	InChI InChI=1S/C25H29N3O3/c1-18-22(10-7-11-23(18)20-8-5-4-6-9-20)17-31-24-13-12-21(25(28-24)30-3)16-26-14-15-27-19(2)29/h4-13,26H,14-17H2,1-3H3,(H,27,29); Key:JEDPSOYOYVELLZ-UHFFFAOYSA-N;

BMS-202 is a small-molecule drug PD-L1 inhibitor developed by Bristol-Myers Squibb which displays significant anti-tumor activity against glioblastoma (GBM) cells.^[1]In addition, BMS-202 has an inhibitory effect on both PD-L1-expressing cancer cells and activated T cells.^[2]

References

^ "BMS-202, a PD-1/PD-L1 inhibitor, decelerates the pro‑fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways". Immunity, Inflammation and Disease. doi:10.1002/iid3.693.
^ "Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse". Biomedical Research. doi:10.2220/biomedres.40.243.

v t e PD-1 and PD-L1 inhibitors
PD-1 inhibitorsTooltip Programmed cell death protein 1	Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab
PD-L1 inhibitorsTooltip Programmed death-ligand 1	BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189